Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ARG1 | P05089 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11094158 | 0.83 | HTR1A (0.47) | MAPTRAB9ASMN1; SMN2HTR1A | |
| SCHEMBL3040144 | 0.82 | ALDH1A1 (0.53) | MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8443965 | 0.80 | ESR1 (0.56) | MAPTRAB9ASMN1; SMN2HSD17B10HTR1A | |
| SCHEMBL8400794 | 0.78 | CA12 (0.46) | MAPTRAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL8910934 | 0.77 | ESR1 (0.56) | MAPTRAB9ASMN1; SMN2HSD17B10HTR1A | |
| SCHEMBL4351612 | 0.77 | TDP1 (0.66) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL6790333 | 0.73 | TDP1 (0.71) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL30567510 | 0.73 | CREBBP (0.52) | MAPTRAB9AHSD17B10ALDH1A1 | |
| SCHEMBL17219434 | 0.73 | CREBBP (0.52) | MAPTRAB9AHSD17B10ALDH1A1 | |
| SCHEMBL1680720 | 0.71 | MAPT (0.56) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973882-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-6740661-B2 | TRICYCLIC IMINE CONTAINING COMPOUNDS HAVING IMIDAZOLE SUBSTITUENT; ANTITUMOR AGENTS | SCHERING CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20020103207-A1 | Farnesyl protein transferase inhibitors | TAVERAS ARTHUR G (US) | 2002-08-01 | — | — | US | disclosed |
| US-6372747-B1 | ENZYME INHIBITORS AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2002-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | TLR8 4872/4885MAPT 3135/4885RAB9A 496/4885 |
| US-20020103207-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, ACAT2 | TLR8 4535/4885MAPT 3759/4885RAB9A 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.